Arbutus Biopharma Corporation (ABUS) reported their Q2 2024 results with a total revenue of $1.726 million, indicating a significant decline of 62.89% year-over-year, yet a 12.66% improvement quarter-over-quarter. The company continues to pursue advancements in developing a functional cure for Hepatitis B, recently reporting promising Phase 2a trial results regarding their RNAi therapeutic imdusiran mixed with immunomodulators. While the financial results showcase ongoing operating losses, management has restructured to extend their cash runway into Q4 2026, potentially positioning the company favorably for future development. However, the reduction in workforce by 40% and discontinuation of certain trials signal challenges ahead, reflected in the net income loss of $19.796 million for the quarter. Investors should carefully evaluate these developments against their long-term strategies.